Lck Inhibitor 2 | CAS#944795-06-6

MedKoo Cat#: 525894 | Name: Lck Inhibitor 2

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lck Inhibitor 2 is a multi-targeting tyrosine kinases inhibitor including LCK, BTK, LYN, SYK, and TXK.

Chemical Structure

Lck Inhibitor 2

CAS#944795-06-6

Theoretical Analysis

MedKoo Cat#: 525894

Name: Lck Inhibitor 2

CAS#: 944795-06-6

Chemical Formula: C18H17N5O2

Exact Mass: 335.1382

Molecular Weight: 335.37

Elemental Analysis: C, 64.47; H, 5.11; N, 20.88; O, 9.54

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lck Inhibitor 2

IUPAC/Chemical Name

3-[[4-(5-Hydroxy-2-methylanilino)pyrimidin-2-yl]amino]benzamide

InChi Key

SFCBIFOAGRZJNX-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H17N5O2/c1-11-5-6-14(24)10-15(11)22-16-7-8-20-18(23-16)21-13-4-2-3-12(9-13)17(19)25/h2-10,24H,1H3,(H2,19,25)(H2,20,21,22,23)

SMILES Code

O=C(N)C1=CC=CC(NC2=NC=CC(NC3=CC(O)=CC=C3C)=N2)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 335.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Seo HH, Kim SW, Lee CY, Lim KH, Lee J, Lim S, Lee S, Hwang KC. 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine inhibits the proliferation and migration of vascular smooth muscle cells by suppressing ERK and Akt pathways. Eur J Pharmacol. 2017 Mar 5;798:35-42. doi: 10.1016/j.ejphar.2017.02.004. Epub 2017 Feb 6. PubMed PMID: 28185804. 2: Kenmogne LC, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F, Poirier D. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models. PLoS One. 2017 Feb 9;12(2):e0171871. doi: 10.1371/journal.pone.0171871. eCollection 2017. PubMed PMID: 28182747; PubMed Central PMCID: PMC5300232. 3: Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309. PubMed PMID: 27582059. 4: O'Donnell JC, Jackson JG, Robinson MB. Transient Oxygen/Glucose Deprivation Causes a Delayed Loss of Mitochondria and Increases Spontaneous Calcium Signaling in Astrocytic Processes. J Neurosci. 2016 Jul 6;36(27):7109-27. doi: 10.1523/JNEUROSCI.4518-15.2016. PubMed PMID: 27383588; PubMed Central PMCID: PMC4938859. 5: Sharma N, Akhade AS, Qadri A. Src kinases central to T-cell receptor signaling regulate TLR-activated innate immune responses from human T cells. Innate Immun. 2016 Apr;22(3):238-44. doi: 10.1177/1753425916632305. Epub 2016 Feb 16. PubMed PMID: 26888964. 6: Ferrari SM, La Motta C, Sartini S, Baldini E, Materazzi G, Politti U, Ruffilli I, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. Mini Rev Med Chem. 2016;16(2):86-93. Review. PubMed PMID: 26471970. 7: Lhuillier C, Barjon C, Niki T, Gelin A, Praz F, Morales O, Souquere S, Hirashima M, Wei M, Dellis O, Busson P. Impact of Exogenous Galectin-9 on Human T Cells: CONTRIBUTION OF THE T CELL RECEPTOR COMPLEX TO ANTIGEN-INDEPENDENT ACTIVATION BUT NOT TO APOPTOSIS INDUCTION. J Biol Chem. 2015 Jul 3;290(27):16797-811. doi: 10.1074/jbc.M115.661272. Epub 2015 May 6. PubMed PMID: 25947381; PubMed Central PMCID: PMC4505427. 8: Wang HC, Chang FR, Huang TJ, Kuo CY, Tsai YC, Wu CC. (-)-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases. Chem Res Toxicol. 2015 May 18;28(5):897-906. doi: 10.1021/tx500518j. Epub 2015 Apr 21. PubMed PMID: 25856345. 9: Tan Y, Sementino E, Pei J, Kadariya Y, Ito TK, Testa JR. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biol Ther. 2015;16(4):580-8. doi: 10.1080/15384047.2015.1018495. Epub 2015 Mar 20. PubMed PMID: 25793663; PubMed Central PMCID: PMC4622865. 10: Trampont PC, Zhang L, Giles AJ, Walk SF, Gu JJ, Pendergast AM, Ravichandran KS. ShcA regulates thymocyte proliferation through specific transcription factors and a c-Abl-dependent signaling axis. Mol Cell Biol. 2015 Apr;35(8):1462-76. doi: 10.1128/MCB.01084-14. Epub 2015 Feb 17. PubMed PMID: 25691660; PubMed Central PMCID: PMC4372706. 11: Cazzaniga V, Bugarin C, Bardini M, Giordan M, te Kronnie G, Basso G, Biondi A, Fazio G, Cazzaniga G. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients. Oncotarget. 2015 Jan 30;6(3):1569-81. PubMed PMID: 25595912; PubMed Central PMCID: PMC4359315. 12: Trani G, Barker JJ, Bromidge SM, Brookfield FA, Burch JD, Chen Y, Eigenbrot C, Heifetz A, Ismaili MH, Johnson A, Krülle TM, MacKinnon CH, Maghames R, McEwan PA, Montalbetti CA, Ortwine DF, Pérez-Fuertes Y, Vaidya DG, Wang X, Zarrin AA, Pei Z. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK). Bioorg Med Chem Lett. 2014 Dec 15;24(24):5818-23. doi: 10.1016/j.bmcl.2014.10.020. Epub 2014 Oct 12. PubMed PMID: 25455497. 13: Zhang X, Simerly C, Hartnett C, Schatten G, Smithgall TE. Src-family tyrosine kinase activities are essential for differentiation of human embryonic stem cells. Stem Cell Res. 2014 Nov;13(3 Pt A):379-89. doi: 10.1016/j.scr.2014.09.007. Epub 2014 Sep 30. PubMed PMID: 25305536; PubMed Central PMCID: PMC4252886. 14: Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer. 2014 Sep 19;14:681. doi: 10.1186/1471-2407-14-681. PubMed PMID: 25236161; PubMed Central PMCID: PMC4177239. 15: Gunda SK, Narasimha SK, Shaik M. P56(lck) kinase inhibitor studies: a 3D QSAR approach towards designing new drugs from flavonoid derivatives. Int J Comput Biol Drug Des. 2014;7(2-3):278-94. doi: 10.1504/IJCBDD.2014.061648. Epub 2014 May 28. PubMed PMID: 24878734. 16: Wang G, Yan Y, Chen X, Lin C, Li Y. SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway. Biomed Res Int. 2014;2014:682010. doi: 10.1155/2014/682010. Epub 2014 Jan 2. PubMed PMID: 24524084; PubMed Central PMCID: PMC3909973. 17: Lv S, Yi PF, Shen HQ, Zhang LY, Dong HB, Wu SC, Xia F, Guo X, Wei XB, Fu BD. Ginsenoside Rh2-B1 stimulates cell proliferation and IFN-γ production by activating the p38 MAPK and ERK-dependent signaling pathways in CTLL-2 cells. Immunopharmacol Immunotoxicol. 2014 Feb;36(1):43-51. doi: 10.3109/08923973.2013.864669. Epub 2013 Dec 3. PubMed PMID: 24294901. 18: Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, Holle SK, Sindic A, Dobrivojevic M, Pavenstädt H, Ciarimboli G. The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch. 2014 Mar;466(3):517-27. doi: 10.1007/s00424-013-1335-8. Epub 2013 Aug 28. PubMed PMID: 23982114. 19: Tsai YR, Huang LJ, Lin HY, Hung YJ, Lee MR, Kuo SC, Hsu MF, Wang JP. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):507-19. doi: 10.1007/s00210-013-0851-6. Epub 2013 Mar 23. PubMed PMID: 23525454. 20: Wan CP, Gao LX, Hou LF, Yang XQ, He PL, Yang YF, Tang W, Yue JM, Li J, Zuo JP. Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity. Acta Pharmacol Sin. 2013 Apr;34(4):522-30. doi: 10.1038/aps.2012.208. Epub 2013 Mar 25. PubMed PMID: 23524573; PubMed Central PMCID: PMC4002795.